Changes and Clinical Significance of Four Parameters of NLR,LMR,RDW and PLR in Patients with Benign and Malignant Ovarian Tumors
10.3969/j.issn.1671-7414.2018.02.006
- VernacularTitle:卵巢良恶性肿瘤患者血液NLR,LMR,RDW,PLR四项参数的变化及其临床意义
- Author:
Jin-Liang XU
1
;
Dan-Dan DU
;
Zhi-Min ZHAI
;
Jin-Jing GUO
Author Information
1. 安徽医科大学附属阜阳市人民医院妇产科
- Keywords:
ovarian cancer;
neutral grain and lymphocyte ratio;
lymphocyte and monocyte ratio;
platelet and lymphocyte ratio;
red cell distribution width
- From:
Journal of Modern Laboratory Medicine
2018;33(2):16-18,22
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the changes of preoperative blood parameters of ovarian cancer patients.Methods The pop ulation that we studied consisted of 29 patients with ovarian cancer and 30 cases of ovarian benign tumors controls,calculated neutrophils and lymphocytes ratio (NLR),lymphocytes and monocytes ratio (LMR),red blood cell distribution width (RDW),platelet and lymphocyte ratio (PLR) and CA-125 levels.According to the clinical stage of ovarian cancer patients,the differences of NLR,LMR,RDW,PLR and CA 125 were analyzed in different stages.The above parameters were used to draw the ROC curve for ovarian cancer.Results The average NLR,LMR,RDW,PLR and CA 125 value in experimental and controlled were 2.49±1.04 vs 1.46±0.45,4.48±1.56 vs 6.67±1.87,175.35±62.86 vs 127.11±41.99,(12.98± 0.98)％ vs (12.48±0.76)％ and (355.9±369.73)U/ml vs (12.87±6.91)U/ml respectively.The differences were statistically significant (t =4.979.4.879.3.477,2.188,5.082,all P＜0.05).(Ⅰ + Ⅱ) stage and (Ⅲ +Ⅳ) stage of ovarian cancer patients m the above mentioned parameters mean differences were statistically significant (t=3.379,2.740,3.855,2.940,3.226,all P＜0.05).The area under ROC of NLR,LMR,RDW,PLR and CA 125 value in diagnosing ovarian cancer were 0.874,0.823,0.749,0.680 and 0.905 respectively.Conclusion Some blood routine parameters can be used to identify benign and malignant ovarian tumors,and have positive significance in the clinical staging of ovarian cancer.
